ArticleInternational journal of molecular sciences2026
COPS7B Drives Malignant Progression of Glioblastoma Through Translational Upregulation of the Downstream Functional Effector CLU.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Glioblastoma (GBM) is a highly aggressive primary malignant brain tumor, featuring diffuse infiltrative growth and poor clinical outcomes, which underscores the need to delineate the molecular mechanisms driving its malignant progression. COP9 signalosome subunit 7B (COPS7B), a core component of the conserved COP9 signalosome complex, is significantly upregulated in GBM tissues; however, its biological function and regulatory mechanism in GBM remain largely elusive. Here, we found that elevated COPS7B expression was positively correlated with glioma pathological grade and adverse prognosis in histologically and molecularly confirmed GBM patients. Functional assays demonstrated that COPS7B markedly promoted the proliferation, migration, and invasion of GBM cells in vitro, while COPS7B knockdown exerted the opposite suppressive effects. Mechanistically, we identified clusterin (CLU) as a key downstream functional effector of COPS7B in GBM. COPS7B upregulated CLU protein abundance by enhancing the translation efficiency of CLU mRNA, without altering its transcriptional level or protein stability. Functional rescue experiments further confirmed that CLU is indispensable for COPS7B-mediated malignancy-driving phenotypes in GBM, and transcriptomic analysis revealed that the progression-promoting effect of CLU was tightly associated with the activation of tumor-related signaling cascades, including the ERK and MAPK pathways, as well as the regulation of cell growth, invasion, and migration. Collectively, this study not only reveals a critical role of COPS7B in driving GBM malignant progression but also delineates a novel COPS7B-CLU regulatory axis that drives GBM aggressive phenotypes via activation of mitogenic signaling, suggesting candidate targets for further translational investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.